Using Fetuin A to Predict Kidney Function Decline in Patients with High Blood Pressure
Modified Urine Fetuin A as a Predictor of Deterioration of Renal Function in Patients With Resistant and Non-resistant Hypertension
This study is testing if a substance in urine called Fetuin A can help predict kidney problems in people with high blood pressure.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | University Hospital Ostrava Academic / other |
| Locations | 1 site (Ostrava, Czech Republic) |
| Trial ID | NCT05963126 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the potential of modified human urine Fetuin A as an early biomarker for predicting the deterioration of renal function in patients with arterial hypertension. Current methods for assessing kidney function often fail to detect early impairment, particularly in patients with diabetes who do not show microalbuminuria. By focusing on hypertonic patients, this study seeks to fill a gap in existing research regarding the predictive capabilities of urine Fetuin A. The study will involve monitoring patients treated for arterial hypertension without any interventions.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with arterial hypertension who are being treated with at least one antihypertensive agent.
Not a fit: Patients with diabetes mellitus, severe hypertension, or those undergoing renal replacement therapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection of kidney disease in patients with high blood pressure, allowing for timely interventions.
How similar studies have performed: While studies on urine Fetuin A in other contexts exist, this specific approach in hypertonic patients is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Arterial hypertension treated by at least one antihypertensive agent Exclusion Criteria: * Diabetes mellitus of any type, defined as fasting glucose \>7,0 mmol/l or any glycemia \>11,0 mmol/l, or HbA1c\>48 mmol/mol * Decompensated arterial hypertension defined as office blood pressure \>180/110 mmHg or on Ambulatory Blood Pressure Monitoring (ABPM) * Patient with renal replacement therapy * Present rheumatoid disease (rheumatoid arthritis, systemic lupus, sclerodermia, dermatomyositis, Inflammatory Bowel Disease, etc.), positivity of antinuclear antibody (ANA) / extractable nuclear antigen (ENA) screening * Acute infection defined as C-Reactive Protein (CRP) \>50 mg/l * Severe impairment of liver function defined as cirrhosis, Alanine Transaminase or ASpartate Transferase (ALT or AST) \>10 µkat/l * Terminal incurable illness
Where this trial is running
Ostrava, Czech Republic
- University Hospital Ostrava, - Department of Internal Medicine and Cardiology — Ostrava, Czech Republic, Czechia (Recruiting)
Study contacts
- Principal investigator: Zdeněk Ramík, MD — University Hospital Ostrava
- Study coordinator: Jiří Hynčica
- Email: jiri.hyncica@fno.cz
- Phone: 0042059737
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.